Shares Held by Insiders

Fully Diluted Shares Held by Insiders

Date

Name

Buy/Sell

$ Value

# Shares

Avg. Price

Title

Chief Executive Officer

Alaunos Therapeutics, Inc., a clinical-stage oncology-focused cell therapy company, develops adoptive TCR engineered T-cell therapies. It develops TCR Library, which is in Phase I/II clinical trial for 12 TCRs reactive to mutated KRAS, TP53, and EGFR from its TCR library for the treatment of non-small cell lung, colorectal, endometrial, pancreatic, ovarian, and bile duct cancers; hunTR, a human neoantigen T-cell receptor engine. The company has a license agreement with PGEN Therapeutics, Inc.; research and development agreement with The University of Texas MD Anderson Cancer Center; and a patent license agreement, and research and development agreement with the National Cancer Institute. The company was formerly known as ZIOPHARM Oncology, Inc. and changed its name to Alaunos Therapeutics, Inc. in January 2022. Alaunos Therapeutics, Inc. was founded in 2003 and is headquartered in Houston, Texas.

Alaunos Therapeutics, Inc., a clinical-stage oncology-focused cell therapy company, develops adoptive TCR engineered T-cell therapies.

Datesorted ascending	Name	Buy/Sell	$ Value	# Shares	Avg. Price	Title
2023-09-01	Premium	sold	Premium	Premium	Premium	Chief Executive Officer
2022-11-29	Premium	bought	Premium	Premium	Premium	-
2022-11-29	Premium	bought	Premium	Premium	Premium	-
2022-08-30	Premium	sold (taxes)	Premium	Premium	Premium	Chief Executive Officer
2022-06-22	Premium	acquired	Premium	Premium	Premium	-
2022-06-22	Premium	acquired	Premium	Premium	Premium	-
2022-06-22	Premium	acquired	Premium	Premium	Premium	-
2022-06-22	Premium	acquired	Premium	Premium	Premium	-
2022-06-22	Premium	acquired	Premium	Premium	Premium	-
2022-06-22	Premium	acquired	Premium	Premium	Premium	-

TCRT - Alaunos Therapeutics, Inc. Stock Price, Fair Value and News

Latest Insider Trading transactions for TCRT